Persistent pricing pressure in US generics and API
Pricing pressure in US generics and API businesses persisted during the quarter, partially offset by cost efficiencies.
APLLTD / Q3-FY26 / risks
Keep the risk register visible.
Alembic Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
India branded business underperformance
India branded business grew only 6% YoY, below market growth, and management has not provided a clear timeline for improvement beyond Q1 FY27.
Pivya launch margin drag
The branded product Pivya launch will impact near-term profitability, with management unable to quantify the margin impact.
Dependence on injectable and complex generics for future growth
Management expects injectables and complex generics to drive US growth over the next 2-3 years, but approvals and ramp-up remain uncertain.